LSD1 neurospecific alternative splicing controls neuronal excitability in mouse models of epilepsy

Cerebral Cortex

Volumn 25, Issue 9, 2015, Pages 2729-2740

  Rusconi, Francesco ^a   Paganini, Leda ^a   Braida, Daniela ^a   Ponzoni, Luisa ^a   Toffolo, Emanuela ^a   Maroli, Annalisa ^a   Landsberger, Nicoletta ^b,c   Bedogni, Francesco ^c   Turco, Emilia ^d   Pattini, Linda ^e   Altruda, Fiorella ^d   De Biasi, Silvia ^a   Sala, Mariaelvina ^a,f   Battaglioli, Elena ^a,f  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF INSUBRIA   (Italy)

^c SAN RAFFAELE HOSPITAL   (Italy)

^d UNIVERSITY OF TURIN   (Italy)

^e POLITECNICO DI MILANO   (Italy)

^f CNR   (Italy)

Author keywords

Alternative splicing; Epigenetics; Epilepsy; Rett syndrome; Transcription

Indexed keywords

HISTONE DEMETHYLASE; LYSINE SPECIFIC DEMETHYLASE 1; NOVA1 PROTEIN; PILOCARPINE; PROTEIN; PROTEIN NSR100; RNA; UNCLASSIFIED DRUG; AOF2 PROTEIN, MOUSE; NERVE PROTEIN; NOVA ANTIGEN; RNA BINDING PROTEIN; TUMOR ANTIGEN;

ALTERNATIVE RNA SPLICING; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN; CONTROLLED STUDY; DOWN REGULATION; ELECTROENCEPHALOGRAM; EMBRYO; EPILEPTIC STATE; EPILEPTOGENESIS; EXON; FEMALE; GENETIC VARIABILITY; HUMAN; HUMAN CELL; IN VIVO STUDY; MALE; MOUSE; NERVE CELL EXCITABILITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETT SYNDROME; SEIZURE SUSCEPTIBILITY; SILENCER GENE; UPREGULATION; ANALYSIS OF VARIANCE; ANIMAL; C57BL MOUSE; CHROMATIN IMMUNOPRECIPITATION; DISEASE MODEL; ELECTROENCEPHALOGRAPHY; EPILEPSY; GENETIC TRANSFECTION; GENETICS; METABOLISM; NERVE CELL; NEUROBLASTOMA; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; TRANSGENIC MOUSE; TUMOR CELL LINE;

ALTERNATIVE SPLICING; ANALYSIS OF VARIANCE; ANIMALS; ANTIGENS, NEOPLASM; BRAIN; CELL LINE, TUMOR; CHROMATIN IMMUNOPRECIPITATION; DISEASE MODELS, ANIMAL; DOWN-REGULATION; ELECTROENCEPHALOGRAPHY; EPILEPSY; HISTONE DEMETHYLASES; HUMANS; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NERVE TISSUE PROTEINS; NEUROBLASTOMA; NEURONS; RNA-BINDING PROTEINS; TRANSFECTION;

EID: 84965187315     PISSN: 10473211     EISSN: 14602199     Source Type: Journal    
DOI: 10.1093/cercor/bhu070     Document Type: Article

References (42)

1. Adamo A, Barrero MJ, Izpisua Belmonte JC 2011. LSD1 and pluripotency: a new player in the network. Cell Cycle. 10: 3215-3216.
2. Baralle D, Baralle M. 2005. Splicing in action: assessing disease causing sequence changes. J Med Genet. 42: 737-748.
3. Baralle M, Baralle D, De Conti L, Mattocks C, Whittaker J, Knezevich A, Ffrench-Constant C, Baralle FE. 2003. Identification of a mutation that perturbs NF1 agene splicing using genomic DNA samples and a minigene assay. J Med Genet. 40: 220-222.
4. Ben-Shachar S, Chahrour M, Thaller C, Shaw CA, Zoghbi HY. 2009. Mouse models of MeCP2 disorders share gene expression changes in the cerebellum and hypothalamus. Hum Mol Genet. 18: 2431-2442.
5. Boutz PL, Stoilov P, Li Q, Lin CH, Chawla G, Ostrow K, Shiue L, Ares M, Black DL. 2007. A post-transcriptional regulatory switch in polypyrimidine tract-binding proteins reprograms alternative splicing in developing neurons. Genes Dev. 21: 1636-1652.
6. Braunschweig U, Gueroussov S, Plocik AM, Graveley BR, Blencowe BJ. 2013. Dynamic integration of splicing within gene regulatory pathways. Cell. 152: 1252-1269.
7. Calarco JA, Superina S, O'Hanlon D, Gabut M, Raj B, Pan Q, Skalska U, Clarke L, Gelinas D, van der Kooy D et al. 2009. Regulation of vertebrate nervous system alternative splicing and development by an SR-related protein. Cell. 138: 898-910.
8. Chahrour M, Jung SY, Shaw C, Zhou X, Wong ST, Qin J, Zoghbi HY. 2008. MeCP2, a key contributor to neurological disease, activates and represses transcription. Science. 320: 1224-1229.
9. Chahrour M, Zoghbi HY. 2007. The story of Rett syndrome: from clinic to neurobiology. Neuron. 56: 422-437.
10. Dolce A, Ben-Zeev B, Naidu S, Kossoff EH. 2013. Rett syndrome and epilepsy: an update for child neurologists. Pediatr Neurol. 48: 337-345.
11. Ellis JD, Barrios-Rodiles M, Colak R, Irimia M, Kim T, Calarco JA, Wang X, Pan Q, O'Hanlon D, Kim PM et al. 2012. Tissue-specific alternative splicing remodels protein-protein interaction networks. Mol Cell. 46: 884-892.
12. Eom T, Zhang C, Wang H, Lay K, Fak J, Noebels JL, Darnell RB. 2013. NOVA-dependent regulation of cryptic NMD exons controls synaptic protein levels after seizure. Elife. 2: e00178.
13. Forneris F, Binda C, Vanoni MA, Battaglioli E, Mattevi A. 2005. Human histone demethylase LSD1 reads the histone code. J Biol Chem. 280: 41360-41365.
14. Garriga-Canut M, Schoenike B, Qazi R, Bergendahl K, Daley TJ, Pfender RM, Morrison JF, Ockuly J, Stafstrom C, Sutula T et al. 2006. 2-Deoxy-D-glucose reduces epilepsy progression by NRSF-CtBP-dependent metabolic regulation of chromatin structure. Nat Neurosci. 9: 1382-1387.
15. Guy J, Cheval H, Selfridge J, Bird A. 2011. The role of MeCP2 in the brain. Annu Rev Cell Dev Biol. 27: 631-652.
16. Guy J, Hendrich B, Holmes M, Martin JE, Bird A. 2001. A mouse Mecp2-null mutation causes neurological symptoms that mimic Rett syndrome. Nat Genet. 27: 322-326.
17. Irimia M, Blencowe BJ. 2012. Alternative splicing: decoding an expansive regulatory layer. Curr Opin Cell Biol. 24: 323-332.
18. Jelen N, Ule J, Zivin M. 2010. Cholinergic regulation of striatal Nova mRNAs. Neuroscience. 169: 619-627.
19. Kalsotra A, Cooper TA. 2011. Functional consequences of developmentally regulated alternative splicing. Nat Rev Genet. 12: 715-729.
20. Lee JA, Tang ZZ, Black DL. 2009. An inducible change in Fox-1/A2BP1 splicing modulates the alternative splicing of downstream neuronal target exons. Genes Dev. 23: 2284-2293.
21. Li Q, Lee JA, Black DL. 2007. Neuronal regulation of alternative pre-mRNA splicing. Nat Rev Neurosci. 8: 819-831.
22. Licatalosi DD, Darnell RB. 2010. RNA processing and its regulation: global insights into biological networks. Nat Rev Genet. 11: 75-87.
23. Lipscombe D. 2005. Neuronal proteins custom designed by alternative splicing. Curr Opin Neurobiol. 15: 358-363.
24. Liu P, Jenkins NA, Copeland NG. 2003. A highly efficient recombineering-based method for generating conditional knockout mutations. Genome Res. 13: 476-484.
25. McKee AE, Silver PA. 2007. Systems perspectives on mRNA processing. Cell Res. 17: 581-590.
26. Nakano Y, Jahan I, Bonde G, Sun X, Hildebrand MS, Engelhardt JF, Smith RJ, Cornell RA, Fritzsch B, Bánfi B. 2012. A mutation in the Srrm4 gene causes alternative splicing defects and deafness in the Bronx waltzer mouse. PLoS Genet. 8: e1002966.
27. Nan X, Bird A. 2001. The biological functions of the methyl-CpG-binding protein MeCP2 and its implication in Rett syndrome. Brain Dev. 23(Suppl 1):S32-S37.
28. Racine R, Okujava V, Chipashvili S. 1972. Modification of seizure activity by electrical stimulation. 3. Mechanisms. Electroencephalogr Clin Neurophysiol. 32: 295-299.
29. Raj B, O'Hanlon D, Vessey JP, Pan Q, Ray D, Buckley NJ, Miller FD, Blencowe BJ. 2011. Cross-regulation between an alternative splicing activator and a transcription repressor controls neurogenesis. Mol Cell. 43: 843-850.
30. Roopra A, Dingledine R, Hsieh J. 2012. Epigenetics and epilepsy. Epilepsia. 53 (Suppl 9): 2-10.
31. Rusconi F, Mancinelli E, Colombo G, Cardani R, Da Riva L, Bongarzone I, Meola G, Zippel R. 2010. Proteome profile in Myotonic Dystrophy type 2 myotubes reveals dysfunction in protein processing and mitochondrial pathways. Neurobiol Dis. 38: 273-280.
32. Skene PJ, Illingworth RS, Webb S, Kerr AR, James KD, Turner DJ, Andrews R, Bird AP. 2010. Neuronal MeCP2 is expressed at near histone-octamer levels and globally alters the chromatin state. Mol Cell. 37: 457-468.
33. Sharma AK, Reams RY, Jordan WH, Miller MA, Thacker HL, Snyder PW. 2007. Mesial temporal lobe epilepsy: pathogenesis, induced rodent models and lesions. Toxicol Pathol. 35: 984-999.
34. Shepherd GM, Katz DM. 2011. Synaptic microcircuit dysfunction in genetic models of neurodevelopmental disorders: focus on Mecp2 and Met. Curr Opin Neurobiol. 21: 827-833.
35. Shi Y, Lan F, Matson C, Mulligan P, Whetstine JR, Cole PA, Casero RA. 2004. Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell. 119: 941-953.
36. Shibley H, Smith BN. 2002. Pilocarpine-induced status epilepticus results in mossy fiber sprouting and spontaneous seizures in C57BL/6 and CD-1 mice. Epilepsy Res. 49: 109-120.
37. Stojic L, Jasencakova Z, Prezioso C, Stützer A, Bodega B, Pasini D, Klingberg R, Mozzetta C, Margueron R, Puri PL et al. 2011. Chromatin regulated interchange between polycomb repressive complex 2 (PRC2)-Ezh2 and PRC2-Ezh1 complexes controls myogenin activation in skeletal muscle cells. Epigenetics Chromatin. 4: 16.
38. Toffolo E, Rusconi F, Paganini L, Tortorici M, Pilotto S, Heise C, Verpelli C, Tedeschi G, Maffioli E, Sala C et al. 2014. Phosphorylation of neuronal lysine-specific demethylase 1LSD1/KDM1A impairs transcriptional repression by regulating interaction with CoREST and histone deacetylases HDAC1/2. J Neurochem. 128: 603-616.
39. Ule J, Darnell RB. 2006. RNA binding proteins and the regulation of neuronal synaptic plasticity. Curr Opin Neurobiol. 16: 102-110.
40. Zhang C, Frias MA, Mele A, Ruggiu M, Eom T, Marney CB, Wang H, Licatalosi DD, Fak JJ, Darnell RB. 2010. Integrative modeling defines the Nova splicing-regulatory network and its combinatorial controls. Science. 329: 439-443.
41. Zhang L, He J, Jugloff DG, Eubanks JH. 2008. The MeCP2-null mouse hippocampus displays altered basal inhibitory rhythms and is prone to hyperexcitability. Hippocampus. 18: 294-309.
42. Zibetti C, Adamo A, Binda C, Forneris F, Toffolo E, Verpelli C, Ginelli E, Mattevi A, Sala C, Battaglioli E. 2010. Alternative splicing of the histone demethylase LSD1/KDM1 contributes to the modulation of neurite morphogenesis in the mammalian nervous system. J Neurosci. 30: 2521-2532.